Holen Sie sich die Stockscreener-App
16.68
0.36%
0.06
Handel nachbörslich:
17.75
1.07
+6.41%
Schlusskurs vom Vortag:
$16.62
Offen:
$16.81
24-Stunden-Volumen:
233.57K
Relative Volume:
0.45
Marktkapitalisierung:
$740.56M
Einnahmen:
$9.00M
Nettoeinkommen (Verlust:
$-80.61M
KGV:
-7.4358
EPS:
-2.2432
Netto-Cashflow:
$-82.35M
1W Leistung:
-4.36%
1M Leistung:
-4.69%
6M Leistung:
+122.40%
1J Leistung:
+301.93%
1-Tages-Spanne:
$16.18
$17.00
1-Wochen-Bereich:
$16.05
$17.31
52-Wochen-Spanne:
$3.67
$24.00
Bioage Labs Inc Stock (BIOA) Company Profile
Firmenname
Bioage Labs Inc
Sektor
Telefon
510-806-1445
Adresse
5885 HOLLIS STREET, EMERYVILLE
Compare BIOA vs TAK, ZTS, TEVA, HLN, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIOA
Bioage Labs Inc
|
16.68 | 737.89M | 9.00M | -80.61M | -82.35M | -2.2432 |
TAK
Takeda Pharmaceutical Co Adr
|
16.55 | 52.32B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
112.54 | 47.38B | 9.47B | 2.67B | 2.28B | 6.0218 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.86 | 41.16B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.17 | 41.02B | 14.54B | 2.22B | 2.58B | 0.4871 |
UTHR
United Therapeutics Corp
|
572.20 | 24.67B | 3.18B | 1.33B | 1.04B | 27.90 |
Bioage Labs Inc Stock (BIOA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-27 | Eingeleitet | Needham | Buy |
| 2026-02-25 | Eingeleitet | Oppenheimer | Outperform |
| 2026-02-18 | Hochstufung | Jefferies | Hold → Buy |
| 2026-01-27 | Eingeleitet | Piper Sandler | Overweight |
| 2025-12-05 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2025-10-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-02-28 | Eingeleitet | William Blair | Mkt Perform |
| 2024-12-10 | Herabstufung | Morgan Stanley | Overweight → Underweight |
| 2024-12-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-12-09 | Herabstufung | Jefferies | Buy → Hold |
| 2024-10-21 | Eingeleitet | Citigroup | Buy |
| 2024-10-21 | Eingeleitet | Jefferies | Buy |
| 2024-10-21 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Bioage Labs Inc Aktie (BIOA) Neueste Nachrichten
BioAge to preview early data for heart and retinal disease drug - Stock Titan
BioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026 - The Manila Times
BlackRock (NYSE: BIOA) reports 2.24M shares of BioAge; 5.03% stake - Stock Titan
BioAge Labs (NASDAQ:BIOA) Trading 8.6% HigherHere's Why - MarketBeat
BioAge Labs plans up to $75M public stock offering; shares down - MSN
Wall Street Zen Downgrades BioAge Labs (NASDAQ:BIOA) to Sell - MarketBeat
BioAge Labs (BIOA) CFO exercises 3,542 options, now holds 36,575 shares - Stock Titan
BioAge Labs Touts Phase 1 BGE-102 Data, Citing 86% hs-CRP Drop and Clean Safety Profile - MarketBeat
BIOA FINAL DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages BioAge Labs, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 10 Deadline in Securities Class ActionBIOA - TMX Newsfile
BIOA SEC FilingsBioAge Labs Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
BioAge Labs (NASDAQ:BIOA) Stock Price Down 6.1%Time to Sell? - MarketBeat
BIOA (BioAge Labs Inc.) Q4 2025 loss narrows more than expected, shares climb 8.83 percent on investor enthusiasm.Management Guidance - Xã Vĩnh Công
[ARS] BioAge Labs, Inc. SEC Filing - Stock Titan
Jefferies reiterates BioAge Labs stock rating on dose data By Investing.com - Investing.com South Africa
Directors and auditor up for approval at BioAge Labs (NASDAQ: BIOA) 2026 meeting - Stock Titan
Jefferies reiterates BioAge Labs stock rating on dose data - Investing.com
BioAge Labs (BIOA): Phase 1 BGE-102 Data Reinforce Best-in-Class NLRP3 Potential and De-Risk 2026 Cardiovascular Phase 2, Supporting Buy Rating - TipRanks
BioAge says early data suggest ‘best-in-class’ potential for inflammation drug - BioPharma Dive
BioAge Labs Stock Gains After Positive Early Data And Pipeline Plans - Benzinga
BioAge Reports Positive Phase 1 Data for BGE-102 - Lifespan Research Institute
Wall Street Analysts Predict an 183.67% Upside in BioAge Labs, Inc. (BIOA): Here's What You Should Know - Yahoo Finance
BioAge's BGE-102 Shows Deep Reductions In Inflammation Markers In Phase 1 Trial, Stock Up - RTTNews
BioAge reports Phase 1 results for NLRP3 inhibitor BGE-102 - Investing.com
BioAge reports Phase 1 results for NLRP3 inhibitor BGE-102 By Investing.com - Investing.com Canada
BGE-102 60 mg once daily achieves equivalent hsCRP reduction as 120 mg, BioAge Labs, Inc. finds - Traders Union
BioAge Reports Positive Phase 1 Data for BGE-102, a Novel - GlobeNewswire
BioAge Labs (BIOA) Stock: Should You Take Exposure (Volatility Increases) 2026-04-20Earnings Beat Stocks - Xã Thanh Hà
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 10, 2025 in BioAge Labs, Inc. LawsuitBIOA - ACCESS Newswire
BioAge Labs (NASDAQ:BIOA) Shares Up 10.3%Still a Buy? - MarketBeat
Needham Maintains BioAge Labs(BIOA.US) With Buy Rating, Maintains Target Price $50 - 富途牛牛
BioAge Labs Highlights BGE-102 Catalysts, DME Study Plans and $285M Cash at Needham Conference - MarketBeat
BioAge LabsOral NLRP3 Inhibitor Could Establish PoC In CV This Year (NASDAQ:BIOA) - Seeking Alpha
BioAge Labs (BIOA) price target increased by 44.67% to 44.27 - MSN
BioAge Labs to Present at 25th Annual Needham Virtual Healthcare Conference - The Manila Times
BioAge CEO's April 16 fireside chat will stream live online - Stock Titan
Weekly Trades: Is BioAge Labs Inc in accumulation or distribution phaseMarket Activity Report & Free High Return Stock Watch Alerts - baoquankhu1.vn
BGE-102 data inspires confidence for BioAge Labs (BIOA) - MSN
Fund Flows: Can BioAge Labs Inc expand its profit margins2026 Selloffs & Weekly Consistent Profit Watchlists - baoquankhu1.vn
BioAge Labs (NASDAQ:BIOA) Shares Down 6%Here's What Happened - MarketBeat
The $120 Billion Longevity Economy Is Shifting From Supplements to Therapies That Target Aging Itself — And One Small-Cap Is Producing An Anti-Aging Protein From Encapsulated Cells - Baystreet.ca
BioAge Labs, Inc. (NASDAQ:BIOA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Is Amgen (AMGN) Outperforming Other Medical Stocks This Year? - Yahoo Finance Singapore
Will BioAge Labs (BIOA) Stock Beat Expectations | Price at $17.44, Down 0.34%Crowd Sentiment Stocks - Cổng thông tin điện tử tỉnh Tây Ninh
Sectors Review: Can BioAge Labs Inc expand its profit marginsOptions Play & Daily Momentum Trading Reports - baoquankhu1.vn
BioAge Labs (BIOA) CMO Rubin sells $157k in shares - Investing.com UK
BioAge Labs (BIOA) CMO Rubin sells $157k in shares By Investing.com - Investing.com South Africa
BioAge Labs (NASDAQ: BIOA) CMO exercises options, sells 8,820 shares at $17.81 - Stock Titan
BIOA Stock Analysis: BioAge Labs Inc. Biotech 1.3% Daily Dip Review at $17.5 - Cổng thông tin điện tử tỉnh Tây Ninh
Finanzdaten der Bioage Labs Inc-Aktie (BIOA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.67%
2.13%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):